Background: Cutaneous leishmaniasis (CL) is a major world problem. Several types of treatment regimens have been suggested. Imiquimod demonstrated a leishmanicidal activity by increasing local cytokine production. The aim of this study was to determine the efficacy of topical 5% imiquimod with cryotherapy vs. intralesional meglumine antimoniate (MA) in treatment of anthroponotic (dry type) CL. ...

Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which BRAF V600E kinase–activating mutation plays pathogenetic role. In clinical trials involving patients with refractory or relapsed HCL, the targeting of oral inhibitor vemurafenib led to response 91% patients; 35% had complete response. However, median relapse-free survival was only 9 months after treatment stopped.

Abstract We identified the lowest composition necessary to generate a vaccination adjuvant that promotes Treg response following immunization in mice and named it “complete tolerogenic adjuvant.” This novel may allow us utilize well-established “antigen plus adjuvant” method of induce cell-mediated antigen-specific immunosuppression. The minimal is dexamethasone, rapamycin, monophosphoryl lipid...

OBJECTIVE To report the experience in three Brazilian institutions with the use of rituximab in patients with different clinical forms of lupus erythematosus systemic in activity. METHODS The study consisted of a sample of 17 patients with LES, who were already being treated, but that at some stage of the disease showed refractory symptoms. The patients were subdivided into groups according t...

Background: Rectal cancer patients with a clinical (near-)complete response to neoadjuvant (chemo)radiation are eligible for Watch and Wait (W&W) strategy aiming at organ preservation. For local regrowth total mesorectal excision (TME) is still considered standard of care.